share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K.

Novavax | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K.

諾瓦瓦克斯醫藥 | 4：持股變動聲明-董事 King Rachel K.
美股sec公告 ·  06/15 04:30
牛牛AI助理已提取核心訊息
Rachel K. King, associated with Novavax Inc [NVAX], completed a transaction on June 12, 2024, acquiring 6,670 shares of common stock at no cost. This transaction was classified as an exercise or conversion of derivative security, under the transaction code 'M'. Following this acquisition, King's direct holdings in Novavax common stock increased to a total of 18,920 shares. The transaction has been marked as completed.
Rachel K. King, associated with Novavax Inc [NVAX], completed a transaction on June 12, 2024, acquiring 6,670 shares of common stock at no cost. This transaction was classified as an exercise or conversion of derivative security, under the transaction code 'M'. Following this acquisition, King's direct holdings in Novavax common stock increased to a total of 18,920 shares. The transaction has been marked as completed.
與諾瓦瓦克斯醫藥[NVAX]有關的Rachel K. King於2024年6月12日完成了一筆交易，以零成本獲得了6,670股普通股。此交易被歸類爲衍生證券的行使或轉換，在交易代碼'M'下進行。在此次收購後，King在諾瓦瓦克斯共同股份的直接持股增加到18,920股。該交易已標記爲已完成。
與諾瓦瓦克斯醫藥[NVAX]有關的Rachel K. King於2024年6月12日完成了一筆交易，以零成本獲得了6,670股普通股。此交易被歸類爲衍生證券的行使或轉換，在交易代碼'M'下進行。在此次收購後，King在諾瓦瓦克斯共同股份的直接持股增加到18,920股。該交易已標記爲已完成。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。